Fresenius announced a €200 million corporate venture capital fund to back emerging biotech talent through its Fresenius Ventures program over the next five years. The structure is designed to supply early funding capacity as the company expands innovation sourcing and partnership options. The move aligns Fresenius with other large healthcare groups building venture arms to support translational bets before clinical de-risking. In parallel, investors will watch whether the fund concentrates on specific modalities linked to Fresenius’ core businesses. —